Tome Biosciences is a technology company.
Tome Biosciences has raised $210.0M across 1 funding round.
Tome Biosciences has raised $210.0M in total across 1 funding round.
Tome Biosciences has raised $210.0M in total across 1 funding round.
Tome Biosciences's investors include Andreessen Horowitz, ARCH Venture Partners, Bessemer Venture Partners, Daniel Lynch, GV, Polaris Partners, Timothy A. Springer.
Tome Biosciences was a biotechnology company developing Programmable Genomic Integration (PGI), a gene-editing platform to insert large DNA sequences precisely into the genome without double-strand breaks, targeting diseases like liver disorders, Duchenne muscular dystrophy, and autoimmune conditions.[1][2][3] It served patients with complex genetic diseases and cell therapy developers by enabling safer, more effective genomic reprogramming, likened to a "word processor" for DNA.[2][3] Launched in December 2023 with $213 million in Series A and B funding from investors like a16z Bio + Health, ARCH, and GV, Tome showed early promise but collapsed by November 2024 due to rapid cash burn, layoffs, and shutdown amid high costs and strategic errors.[1][3]
Tome Biosciences emerged from stealth in December 2023, founded by Jonathan Weissman and Omar Abudayyeh, scientists whose MIT-licensed research underpinned PGI, demonstrated in a 2022 Nature paper showing insertion of up to 36,000-base sequences across cell types without DNA breaks.[2][3] CEO Rahul Kakkar, a physician and serial entrepreneur who sold his prior company for nearly $2 billion, led the team alongside CSO John Finn (ex-Intellia CRISPR clinician), CTO Matt Barrows (Moderna vaccine scale-up), and operations experts Ed Freedman and Diane Wong.[3] The idea stemmed from advancing beyond CRISPR's limitations, with initial traction from $213 million funding to pursue in vivo liver disease therapies and ex vivo autoimmune cell therapies.[1][2][3] Pivotal early moves included acquiring Replace Therapeutics for $65 million (up to $185 million total) to bolster CRISPR tech, but this strained resources.[1]
Tome rode the genomic medicine 3.0 wave post-CRISPR (Nobel/FDA-approved), addressing limitations in inserting large payloads for hard-to-treat diseases amid booming gene therapy demand.[3] Timing aligned with maturing cell therapy ecosystems and investor enthusiasm for "software-like" DNA editing, fueled by successes like Moderna's scale-up and Intellia's clinic entry.[1][3] Market forces favored it: rising autoimmune/chronic disease prevalence, need for non-breakage editing to avoid off-target risks, and VC influx into biotech (evident in its $213M raise).[2][3] However, Tome highlighted ecosystem risks—high burn rates, premature acquisitions, and data costs—exposing biotech's "valley of death" for pre-clinical platforms, influencing investor caution on unvalidated tech buys.[1]
Tome's swift rise and fall underscore biotech pitfalls: over-expansion, costly acquisitions like Replace Therapeutics, and leadership gaps burned $213 million in under a year, ending in full layoffs by November 2024.[1] No revival signs post-shutdown; assets or IP may have been absorbed quietly, but its PGI tech could resurface via acquirers targeting genomic integration.[1] Trends like AI-accelerated drug design and safer editing (e.g., prime editing evolutions) will shape successors, potentially redeeming Tome's vision in a more capital-efficient ecosystem. This cautionary tale reminds investors that even MIT-backed, VC-fueled platforms must prioritize milestones over hype to endure.
Tome Biosciences has raised $210.0M across 1 funding round. Most recently, it raised $210.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $210.0M Series A | Andreessen Horowitz, ARCH Venture Partners, Bessemer Venture Partners, Daniel Lynch, GV, Polaris Partners, Timothy A. Springer |